ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Abstract Number: 0372

Impact of Gender and Age on Ankylosing Spondylitis Patient Profiles at Golimumab Initiation and 12-Month Outcomes
Abstract Number: 0373

Self-monitoring of Disease Activity with a Smartphone App Is Feasible in Routine Clinical Management of Patients with Axial Spondyloarthritis – a Proof of Concept Study
Abstract Number: 0374

Validation of the Ankylosing Spondylitis Disease Activity Score with a Quick Quantitative Creactiveprotein Assay (ASDAS-qCRP) in Patients with Axial Spondyloarthritis (axSpA): Aprospective, National, Multicenter Study
Abstract Number: 0375

Optimizing a Referral Strategy for Patients with a High Probability of Axial Spondyloarthritis:the Role of Age and Symptom Duration
Abstract Number: 0376

Impact of Patient and Disease Characteristics on Global Functioning and Health in Patients with Axial Spondyloarthritis: A Bayesian Network Analysis of Data from an Early axSpA Cohort
Abstract Number: 0377

The Prevalence of Inflammatory Back Pain and HLA-B27 in a Large Population-Based Cohort in the Netherlands
Abstract Number: 0378

Comparison of Demographic, Clinic and Radiological Features of Axial Spondyloarthritis Patients with and Without Accompanying Familial Mediterranean Fever
Abstract Number: 0379

Pain Sensitivity in Axial Spondyloarthritis – Comparisons Between Patients and Controls, Women and Men, and Between Different Pain Groups
Abstract Number: 0380

Sick Leave and Its Predictors in Early Axial Spondyloarthritis: The Role of Clinical and Socioeconomic Factors. Five-year Data from the DESIR Cohort
Abstract Number: 0381

How Do Clinical and Socioeconomic Factors Impact on Work Disability in Early Axial Spondyloarthritis? Five-year Data from the DESIR Cohort
Abstract Number: 0382

Six-year Results from the Esperanza Cohort: Evaluation of Clinical Features, Disease Activity Measures and Treatment Aspects in Axial and Peripheral Early Spondyloarthritis
Abstract Number: 0383

Differences Between Male vs. Female Presenting with Back Pain in an Integrated Delivery System
Abstract Number: 0384

A Tough Cell: The Argument for a Biomarker of Clinical and Imaging Outcomes in Spondyloarthritis: The Neutrophil Lymphocyte Ratio and the Platelet Lymphocyte Ratio
Abstract Number: 0385

The Diagnostic Utility of Serum interleukin-22 in Patients with Suspected Axial Spondyloarthritis
Abstract Number: 0386

Delay to Diagnosis in Axial Spondyloarthritis: The Gap Is Closing, but Persistent Association with Severe Disease

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].